Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment
Rybelsus, Novo Nordisk’s GLP-1 also known as semaglutide, snagged a label update from the FDA, allowing patients to take it as a first-line treatment for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
